Skip to main content

Table 1 Experimental groups, treatments at different days post PEDV vaccination (dpv), average daily gain (ADG) in grams from dpv 0 to 42 (corresponds to day post challenge 14), length and area under the curve (AUC) of PEDV RNA shedding in feces

From: Evaluation of the efficacy of a commercial inactivated genogroup 2b-based porcine epidemic diarrhea virus (PEDV) vaccine and experimental live genogroup 1b exposure against 2b challenge

Group designation Number of pigs Exposure or vaccination Challenge ADGd Viral shedding in fecesd
Type Adjuvant Genogroup Route Timing dpv 28 dpv 0–42 Length (days) AUC
EXP-IM-1b 7 Experimental live virus Adjuplex™ G1b Intramuscularly dpv 0 PEDV G2b 412.8 ± 29.8A 10.7 ± 1.5A,e 236.6A
EXP-ORAL-1b 8 Experimental live virus None G1b Orally dpv 0 PEDV G2b 385.2 ± 27.0A 5.8 ± 0.3A,B 141.9A
VAC-IM-2b 8 Commercial inactivatedc Amphigen® G2b Intramuscularly dpv 0 and 14 PEDV G2b 402.8 ± 26.1A 2.5 ± 1.6B,C 43.9B
POS-CONTROLa 8 Saline None NA Intramuscularly dpv 0 PEDV G2b 379.8 ± 19.5A 7.5 ± 1.3A 169.0A
NEG-CONTROLb 8 Saline None NA Orally dpv 0 Saline 460.0 ± 22.1A 0.0 ± 0.0C 0.0B
  1. aThe POS-CONTROL group was sham-vaccinated intramuscularly and inoculated with PEDV G2b and served as an unvaccinated, PEDV challenged group.
  2. bThe NEG-CONTROL group was sham-vaccinated orally with saline and sham-inoculated with saline and served as unvaccinated and unchallenged control group.
  3. cPorcine Epidemic Diarrhea Vaccine; Zoetis.
  4. dData presented as group mean ± SEM.
  5. eDifferent superscripts(A,B,C) within a column indicate significant (P < 0.05) different group means.